An Immune‐Enhancing Injectable Hydrogel Loaded with Esketamine and DDP Promotes Painless Immunochemotherapy to Inhibit Breast Cancer Growth

• DOI: 10.1002/adhm.202401373
• Publication Date: 2024-08-09T09:14:11Z
• Authors: Xiali Yin; Yaohua Ke; Ying Liang; Shuxian Zhang; Ziqi Chen; Lixia Yu; Ming Jiang; Qin Liu; Xiaoping Gu
• Keywords: 0301 basic medicine; 0303 health sciences; Research Article

Abstract Chemotherapy is the cornerstone of triple‐negative breast cancer. The poor effectiveness and severe neuropathic pain caused by it have a significant impact on immune system. Studies confirmed that cells in tumor microenvironment (TME), critical roles regulation prognosis. In this study, revealed painless administration Esketamine, combined with Cisplatin (DDP), can exert an anti‐tumor effect, which further boosted hydrogel delivery It also discovered Esketamine DDP co‐loaded Poloxamer Hydrogel (PDEH) induces local immunity increasing mature Dendritic Cells (mDCs) activated T PDEH group while regulatory (Tregs) known as CD4 + CD25 FoxP3 decreased significantly. Finally, , CD8 spleen exhibited increase, suggesting lasting PDEH. This study proposes serve modulator, enhancing effect poloxamer DDP. Along improving microenvironment, potentially alleviate anxiety depression. With its outstanding bio‐safety profile, offers promising new possibilities for clinical therapy.